Skip to main content
Top

17-06-2017 | Breast cancer | Article

Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment

Journal: Breast Cancer Research and Treatment

Authors: Alexander Liede, Carol A. Mansfield, Kelly A. Metcalfe, Melanie A. Price, Carrie Snyder, Henry T. Lynch, Sue Friedman, Justyna Amelio, Joshua Posner, Steven A. Narod, Geoffrey J. Lindeman, D. Gareth Evans, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer

Publisher: Springer US

Abstract

Purpose

Unaffected women who carry BRCA1 or BRCA2 mutations face difficult choices about reducing their breast cancer risk. Understanding their treatment preferences could help us improve patient counseling and inform drug trials. The objective was to explore preferences for various risk-reducing options among women with germline BRCA1/2 mutations using a discrete-choice experiment survey and to compare expressed preferences with actual behaviors.

Methods

A discrete-choice experiment survey was designed wherein women choose between hypothetical treatments to reduce breast cancer risk. The hypothetical treatments were characterized by the extent of breast cancer risk reduction, treatment duration, impact on fertility, hormone levels, risk of uterine cancer, and ease and mode of administration. Data were analyzed using a random-parameters logit model. Women were also asked to express their preference between surgical and chemoprevention options and to report on their actual risk-reduction actions. Women aged 25–55 years with germline BRCA1/2 mutations who were unaffected with breast or ovarian cancer were recruited through research registries at five clinics and a patient advocacy group.

Results

Between January 2015 and March 2016, 622 women completed the survey. Breast cancer risk reduction was the most important consideration expressed, followed by maintaining fertility. Among the subset of women who wished to have children in future, the ability to maintain fertility was the most important factor, followed by the extent of risk reduction. Many more women said they would take a chemoprevention drug than had actually taken chemoprevention.

Conclusions

Women with BRCA1/2 mutations indicated strong preferences for breast cancer risk reduction and maintaining fertility. The expressed desire to have a safe chemoprevention drug available to them was not met by current chemoprevention options.
Literature
1.
Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408CrossRefPubMed
2.
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105(11):812–822CrossRefPubMed
3.
Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am J Hum Genet 56(1):265–271PubMedPubMedCentral
4.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692–695CrossRefPubMed
5.
Thompson D, Easton D (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68(2):410–419CrossRefPubMedPubMedCentral
6.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast cancer linkage consortium. Am J Hum Genet 62(3):676–689CrossRefPubMedPubMedCentral
7.
Lubinski J, Huzarski T, Byrski T, Lynch HT, Cybulski C, Ghadirian P et al (2012) The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 131(1):229–234CrossRefPubMed
8.
Moller P, Maehle L, Vabo A, Clark N, Sun P, Narod SA (2013) Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet 83(1):88–91CrossRefPubMed
9.
Liede A, Karlan BY, Baldwin RL, Platt LD, Kuperstein G, Narod SA (2002) Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol 20(6):1570–1577CrossRefPubMed
10.
Evans DG, Harkness E, Lalloo F, Howell A (2014) Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. J Med Genet 51(9):573–580CrossRefPubMed
11.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22(6):1055–1062CrossRefPubMed
12.
Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L et al (2014) Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 32(15):1547–1553CrossRefPubMedPubMedCentral
13.
Kemel Y, Kauff N, Robson M, Goldfrank D, Wadsworth E, Diiorio T et al (2005) Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers. J Clin Oncol 23(90160):1013CrossRef
14.
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975CrossRefPubMedPubMedCentral
15.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615CrossRefPubMed
16.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622CrossRefPubMed
17.
Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80–87CrossRefPubMedPubMedCentral
18.
Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al (2017) Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109(1):djw177. doi:10.​1093/​jnci/​djw177 CrossRefPubMed
19.
Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collee JM, van Doorn HC, et al (2015) Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 107(5):djv033. doi:10.​1093/​jnci/​djv033 CrossRefPubMed
20.
Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118(9):2281–2284CrossRefPubMed
21.
Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S et al (2013) Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 31(25):3091–3099CrossRefPubMedPubMedCentral
22.
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A et al (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67–75CrossRefPubMedPubMedCentral
23.
Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M et al (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29(13):1664–1669CrossRefPubMedPubMedCentral
24.
Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351(5):427–437CrossRefPubMed
25.
Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW et al (2012) Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 107(1):24–30CrossRefPubMedPubMedCentral
26.
Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C (2002) Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20(2):514–520CrossRefPubMed
27.
Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N et al (2010) Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 78(5):411–417CrossRefPubMed
28.
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P et al (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9):2017–2022CrossRefPubMedPubMedCentral
29.
Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD et al (2009) Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 18(8):2318–2324CrossRefPubMed
30.
Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY (2006) Prevention of BRCA1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804):1467–1470CrossRefPubMed
31.
Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y et al (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 107(7):2989–2994CrossRefPubMedPubMedCentral
32.
Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103–107CrossRefPubMed
33.
Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98–102CrossRefPubMedPubMedCentral
34.
Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L et al (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22(8):933–939CrossRefPubMed
35.
Widschwendter M, Burnell M, Fraser L, Rosenthal AN, Philpott S, Reisel D et al (2015) Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF-kappaB ligand (RANKL), is dysregulated in BRCA mutation carriers. EBioMedicine 2(10):1331–1339CrossRefPubMedPubMedCentral
36.
Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA et al (2011) Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 14(4):403–413CrossRefPubMed
37.
Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103(19):1436–1443CrossRefPubMedPubMedCentral
38.
Kuhfeld W (2010) Marketing research methods in SAS: experimental design, choice, conjoint, and graphical techniques. SAS Institute, Inc., Cary
39.
Kuhfeld W, Tobias R, Garratt M (1994) Efficient experimental design with marketing research applications. J Mark Res 31(4):545–557CrossRef
40.
SAS 9.3 analytics software. SAS Institute, Inc., Cary, 2011
41.
Johnson FR, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA et al (2013) Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 16(1):3–13CrossRef
42.
Horowitz M, Wilner N, Alvarez W (1979) Impact of Event Scale: a measure of subjective stress. Psychosom Med 41(3):209–218CrossRefPubMed
43.
Weiss D, Marmar C (1995) The impact of event scale-revised. In: Wilson J, Kean T (eds) Assessing psychological trauma and PTSD: a practitioner’s handbook, chapter 15. Guildford, New York
44.
NLOGIT software version 5.0. Econometric Software, Inc., Plainview, 2012
45.
Hensher D (2005) Applied choice analysis: a primer. Cambridge University Press, CambridgeCrossRef
46.
Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M et al (2016) RANKL/RANK control BRCA1 mutation-driven mammary tumors. Cell Res 26(7):761–774CrossRefPubMedPubMedCentral
47.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433–443CrossRefPubMed
48.
Donnelly LS, Evans DG, Wiseman J, Fox J, Greenhalgh R, Affen J et al (2014) Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 110(7):1681–1687CrossRefPubMedPubMedCentral
49.
NOLVADEX® (tamoxifen citrate) product information. AstraZeneca Pharmaceuticals LP, Wilmington, 2004
50.
XGEVA® (denosumab) prescribing information. Amgen, Thousand Oaks, 2016